The helminth product ES-62 protects against septic shock via Toll-like receptor 4-dependent autophagosomal degradation of the adaptor MyD88

Nature Immunology

Volumn 12, Issue 4, 2011, Pages 344-353

  Puneet, Padmam ^a,b   McGrath, Mairi A ^c   Tay, Hwee Kee ^c   Al Riyami, Lamyaa ^d   Rzepecka, Justyna ^d   Moochhala, Shabbir M ^e   Pervaiz, Shazib ^a,f   Harnett, Margaret M ^c   Harnett, William ^d   Melendez, Alirio J ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^e DSO NATIONAL LABORATORIES   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLAVULANIC ACID; ES 62; IMMUNOMODULATING AGENT; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; DOWN REGULATION; HELMINTH; HUMAN; IMMUNOMODULATION; INFLAMMATION; MOUSE; NEMATODE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; SEPTIC SHOCK;

ANIMALS; AUTOPHAGY; CELLS, CULTURED; FEMALE; HELMINTH PROTEINS; HUMANS; IMMUNOBLOTTING; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; MYELOID DIFFERENTIATION FACTOR 88; PHAGOSOMES; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 79952907081     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2004     Document Type: Article

References (47)

1. Dombrovskiy, V.Y., Martin, A.A., Sunderram, J. & Paz, H.L. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit. Care Med. 35, 1244-1250 (2007). (Pubitemid 46642649)
2. Padkin, A. et al. Epidemiology of severe sepsis occurring in the frst 24 h in intensive care units in England, Wales, and Northern Ireland. Crit. Care Med. 31, 2332-2338 (2003). (Pubitemid 37100836)
3. Vincent, J.L. et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. J. Am. Med. Assoc. 274, 639-644 (1995).
4. Martin, G.S., Mannino, D.M., Eaton, S. & Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003). (Pubitemid 36437931)
5. Balk, R.A. Severe sepsis and septic shock. Defnitions, epidemiology, and clinical manifestations. Crit. Care Clin. 16, 179-192 (2000). (Pubitemid 30193846)
6. Alexander, C. & Rietschel, E.T. Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res. 7, 167-202 (2001). (Pubitemid 32894573)
7. Janeway, C.A. & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002). (Pubitemid 34293424)
8. Gay, N.J. & Gangloff, M. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem. 76, 141-165 (2007).
9. Doyle, S.L. & O'Neill, L.A. Toll-like receptors: from the discovery of NFκB to new insights into transcriptional regulations in innate immunity. Biochem. Pharmacol. 72, 1102-1113 (2006). (Pubitemid 44468394)
10. O'Neill, L.A. & Bowie, A.G. The family of fve: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7, 353-364 (2007). (Pubitemid 46674493)
11. Parrillo, J.E. et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern. Med. 113, 227-242 (1990). (Pubitemid 20242299)
12. Exley, A.R., Leese, T., Holliday, M.P., Swann, R.A. & Cohen, J. Endotoxaemia and serum tumour necrosis factor as prognostic markers in severe acute pancreatitis. Gut 33, 1126-1128 (1992).
13. Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999). (Pubitemid 29329996)
14. Bustin, M. At the crossroads of necrosis and apoptosis, signaling to multiple cellular targets by HMGB1. Sci. STKE 151, PE39 (2002).
15. Andersson, U. et al. High mobility group 1 protein (HMG-1) stimulates proinfammatory cytokine synthesis in human monocytes. J. Exp. Med. 192, 565-570 (2000). (Pubitemid 30666257)
16. Goodridge, H.S. et al. Immunomodulation via novel use of TLR4 by the flarial nematode phosphorylcholine-containing secreted product, ES-62. J. Immunol. 174, 284-293 (2005). (Pubitemid 40007415)
17. Melendez, A.J. et al. Inhibition of FcεRI-mediated mast cell responses by ES-62, a product of parasitic flarial nematodes. Nat. Med. 13, 1375-1381 (2007). (Pubitemid 350073593)
18. Salomão, R. et al. TLR signaling pathway in patients with sepsis. Shock 1, 73-77 (2008).
19. Weighardt, H. & Holzmann, B. Role of Toll-like receptor responses for sepsis pathogenesis. Immunobiology 212, 715-722 (2008). (Pubitemid 350246264)
20. Delgado, M.A. & Deretic, V. Toll-like receptors in control of immunological autophagy. Cell Death Differ. 16, 976-983 (2009).
21. Deretic, V. Multiple regulatory effector roles of autophagy in immunity. Curr. Opin. Immunol. 21, 53-62 (2009).
22. Klionsky, D.J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4, 151-175 (2008). (Pubitemid 351231180)
23. Mizushima, N. et al. Methods in mammalian autophagy research. Cell 1403, 313-326 (2010).
24. Phillip, D.R. & Parrillo, J.E. Mediator modulation therapy of severe sepsis and septic shock: does it work? Crit. Care Med. 32, 282-286 (2004). (Pubitemid 38125595)
25. Eichacker, P.Q. et al. Risk and the effcacy of antiinfammatory agents: retrospective and confrmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197-1205 (2002). (Pubitemid 35222596)
26. Hubbard, W.J. et al. Cecal ligation and puncture. Shock 1, 52-57 (2005).
27. Li, Y., Karlin, A., Loike, J.D. & Silverstein, S.C. A critical concentration of neutrophils is required for effective bacterial killing in suspension. Proc. Natl. Acad. Sci. USA 99, 8289-8294 (2002). (Pubitemid 34651045)
28. Weighardt, H. et al. Cutting edge: myeloid differentiation factor 88 defciency improves resistance against sepsis caused by polymicrobial infection. J. Immunol. 169, 2823-2827 (2002). (Pubitemid 35013119)
29. Puneet, P. et al. SphK1 regulates proinfammatory responses associated with endotoxin and polymicrobial sepsis. Science 328, 1290-1294 (2010).
30. Sethu, S., Pushparaj, P.N. & Melendez, A.J. TNFα-induced infammatory responses in vivo are mediated by PLD1. PLoS ONE 5, e10506 (2010).
31. Saitoh, T. et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456, 264-268 (2008).
32. Lee, H.-M. et al. Autophagy negatively regulates keratinocyte infammatory responses via scaffolding protein p62/SQSTM1. J. Immunol. 186, 1248-1258 (2011).
33. Goodridge, H.S. et al. Modulation of macrophage cytokine production by ES-62, a secreted product of the flarial nematode Acanthocheilonema viteae. J. Immunol. 167, 940-945 (2001). (Pubitemid 32660851)
34. Henneke, P. et al. Cellular activation, phagocytosis, and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. J. Immunol. 169, 3970-3977 (2002).
35. Horng, T., Barton, G.M. & Medzhitov, R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat. Immunol. 2, 835-841 (2001).
36. Horng, T. et al. The adaptor molecule TIRAP provides signalling specifcity for Tolllike receptors. Nature 420, 329-333 (2002). (Pubitemid 35398189)
37. Doz, E. et al. Acylation determines the toll-like receptor (TLR)-dependent positive versus TLR2-, mannose receptor-, and SIGNR1-independent negative regulation of pro-infammatory cytokines by mycobacterial lipomannan. J. Biol. Chem. 282, 26014-26025 (2007). (Pubitemid 47443801)
38. Ferwerda, B. et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc. Natl. Acad. Sci. USA 106, 10272-10277 (2009).
39. Daubeuf, B. et al. TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J. Immunol. 179, 6107-6114 (2007).
40. Sha, T. et al. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur. J. Pharmacol. 571, 231-239 (2007). (Pubitemid 47379694)
41. Leon, C.G., Tory, R., Jia, J., Sivak, O. & Wasan, K.M. Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm. Res. 25, 1751-1761 (2008).
42. Bone, R.C. et al. Defnitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Crit. Care Med. 20, 864-874 (1992).
43. McInnes, I.B. et al. A novel therapeutic approach targeting articular infammation using the flarial nematode-derived phosphorylcholine-containing glycoprotein ES-62. J. Immunol. 171, 2127-2133 (2003). (Pubitemid 36966497)
44. Harnett, M.M. Laser scanning cytometry: understanding the immune system in situ. Nat. Rev. Immunol. 11, 897-904 (2007). (Pubitemid 350006237)
45. + T cells in vitro and in vivo. J. Immunol. 179, 8026-8034 (2007).
46. 2+ signals, enzyme release, cytokine production and chemotaxis. J. Immunol. 173, 1596-1603 (2004). (Pubitemid 38971589)
47. Ibrahim, F.B., Pang, S.J. & Melendez, A.J. Anaphylatoxin signaling in human neutrophils: A key role for sphingosine kinase. J. Biol. Chem. 279, 44802-44811 (2004). (Pubitemid 39430891)